Figueiredo, Maria,Peeke, Erick,Dewitt, David,Van Geen Hoven, Christina,Troiano, Greg,Wright, James,Song, Young-Ho,Wang, Hong
申请号：
NZ70581213
公开号：
NZ705812A
申请日:
2013.09.16
申请国别(地区):
NZ
年份:
2018
代理人:
摘要：
The present disclosure generally relates to a process for preparing therapeutic nanoparticles, where the process includes combining a therapeutic agent with an organic acid, with an organic solvent to form a first organic phase having about 1 to about 50% solids, wherein the concentration of the organic acid is at least 2 weight percent combining the first organic phase with a first aqueous solution to form a second phase emulsifying the second phase to form an emulsion phase quenching the emulsion phase to form a quenched phase and filtering the solubilized phase to recover the therapeutic nanoparticles, wherein the therapeutic agent is a Bcr-Abl tyrosine-kinase inhibitor selected from imatinib, nilotinib, dasatinib, bosutinib, ponatinib,bafetinib, and pharmaceutically acceptable salts thereof the first polymer is a diblock poly(lactic) acidpoly( ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acidpoly( ethylene)glycol copolymer the organic acid comprises trifluoroacetic acid and the organic solvent comprises benzyl alcohol. The therapeutic nanoparticles may have, for example, improved drug loading and/or drug release properties.
